Sulfonylurea action re-revisited.
Sulfonylureas (SU), commonly used in the treatment of type 2 diabetes mellitus (T2DM), stimulate insulin secretion by inhibiting adenosine triphosphate (ATP)-sensitive K(+) (KATP) channels in pancreatic β-cells. SU are now known to also activate cyclic adenosine monophosphate (cAMP) sensor Epac2 (cAMP-GEFII) to Rap1 signaling, which promotes insulin secretion. The different effects of various SU on Epac2/Rap1 signaling, as well as KATP channels in different tissues, underlie the diverse pancreatic and extra-pancreatic actions of SU. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00014.x, 2010).
Division of Cellular and Molecular Medicine, Department of Physiology and Cell Biology ; Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe ; Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Saitama.
Susumu
S
Seino
Division of Cellular and Molecular Medicine, Department of Physiology and Cell Biology ; Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Chang-Liang
CL
Zhang
Division of Cellular and Molecular Medicine, Department of Physiology and Cell Biology.
Tadao
T
Shibasaki